title: Rapid point-of-care assay of enoxaparin anticoagulant efficacy in whole blood.
abstract: There is the need for a clinical assay to determine the extent to which a patient's blood is effectively anticoagulated by the low-molecular-weight-heparin (LMWH), enoxaparin. There are also urgent clinical situations where it would be important if this could be determined rapidly. The present assay is designed to accomplish this. We only assayed human blood samples that were spiked with known concentrations of enoxaparin. The essential feature of the present assay is the quantification of the efficacy of enoxaparin in a patient's blood sample by degrading it to complete inactivity with heparinase. Two blood samples were drawn into Vacutainer tubes (Becton-Dickenson; Franklin Lakes, NJ) that were spiked with enoxaparin; one sample was digested with heparinase for 5 min at 37 °C, the other sample represented the patient's baseline anticoagulated status. The percent shortening of clotting time in the heparinase-treated sample, as compared to the baseline state, yielded the anticoagulant contribution of enoxaparin. We used the portable, battery operated Hemochron 801 apparatus for measurements of clotting times (International Technidyne Corp., Edison, NJ). The apparatus has 2 thermostatically controlled (37 °C) assay tube wells. We conducted the assays in two types of assay cartridges that are available from the manufacturer of the instrument. One cartridge was modified to increase its sensitivity. We removed the kaolin from the FTK-ACT cartridge by extensive rinsing with distilled water, leaving only the glass surface of the tube, and perhaps the detection magnet, as activators. We called this our minimally activated assay (MAA). The use of a minimally activated assay has been studied by us and others. (2-4) The second cartridge that was studied was an activated partial thromboplastin time (aPTT) assay (A104). This was used as supplied from the manufacturer. The thermostated wells of the instrument were used for both the heparinase digestion and coagulation assays. The assay can be completed within 10 min. The MAA assay showed robust changes in clotting time after heparinase digestion of enoxaparin over a typical clinical concentration range. At 0.2 anti-Xa I.U. of enoxaparin per ml of blood sample, heparinase digestion caused an average decrease of 9.8% (20.4 sec) in clotting time; at 1.0 I.U. per ml of enoxaparin there was a 41.4% decrease (148.8 sec). This report only presents the experimental application of the assay; its value in a clinical setting must still be established.
authors.affiliation: Department of Pharmacology, New York Medical College, NY, USA. mario_inchiosa@nymc.edu
authors.forename: Mario A
authors.initials: MA
authors.lastname: Inchiosa
authors.forename: Suryanarayana
authors.initials: S
authors.lastname: Pothula
authors.forename: Keshar
authors.initials: K
authors.lastname: Kubal
authors.forename: Vajubhai T
authors.initials: VT
authors.lastname: Sanchala
authors.forename: Iris
authors.initials: I
authors.lastname: Navarro
mesh_terms: D000925:Anticoagulants / Q000097:blood* / Q000494:pharmacology*; D001777:Blood Coagulation / Q000187:drug effects*; D001780:Blood Coagulation Tests / Q000379:methods*; D017984:Enoxaparin / Q000097:blood* / Q000494:pharmacology*; D019763:Heparin Lyase / Q000097:blood / Q000737:chemistry; D006801:Humans; D019095:Point-of-Care Systems
chemical_list: D000925:Anticoagulants; D017984:Enoxaparin; D019763:Heparin Lyase